Real-world short-term outcomes after switching to fixed-interval anti-VEGF therapy for neovascular AMD during the COVID-19 pandemic.

ABSTRACT:

SUBMITTER: Reyes AG 

PROVIDER: S-EPMC12505566 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature